Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 534969, 16 pages
http://dx.doi.org/10.1155/2014/534969
Review Article

Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126 Torino, Italy

Received 10 April 2014; Accepted 12 May 2014; Published 3 June 2014

Academic Editor: Zhiqiang Meng

Copyright © 2014 Laura Conti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Korkaya, S. Liu, and M. S. Wicha, “Breast cancer stem cells, cytokine networks, and the tumor microenvironment,” Journal of Clinical Investigation, vol. 121, no. 10, pp. 3804–3809, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Zhou, D. R. Shaffer, D. A. Alvarez Arias et al., “In vivo discovery of immunotherapy targets in the tumour microenvironment,” Nature, vol. 506, no. 7486, pp. 52–57, 2014. View at Publisher · View at Google Scholar
  3. F. Cavallo, R. A. Calogero, and G. Forni, “Are oncoantigens suitable targets for anti-tumour therapy?” Nature Reviews Cancer, vol. 7, no. 9, pp. 707–713, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Iezzi, E. Quaglino, A. Amici, P. L. Lollini, G. Forni, and F. Cavallo, “DNA vaccination against oncoantigens: a promise,” Oncoimmunology, vol. 1, no. 3, pp. 316–325, 2012. View at Publisher · View at Google Scholar
  5. S. Ménard, P. Casalini, M. Campiglio, S. Pupa, R. Agresti, and E. Tagliabue, “HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer,” Annals of Oncology, vol. 12, supplement 1, pp. S15–S19, 2001. View at Google Scholar · View at Scopus
  6. D. J. Slamon, G. M. Clark, and S. G. Wong, “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987. View at Google Scholar · View at Scopus
  7. D. L. Nielsen, M. Andersson, and C. Kamby, “HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors,” Cancer Treatment Reviews, vol. 35, no. 2, pp. 121–136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. J. C. Thery, J. P. Spano, D. Azria, E. Raymond, and F. Penault Llorca, “Resistance to human epidermal growth factor receptor type 2-targeted therapies,” European Journal of Cancer, vol. 50, no. 5, pp. 892–901, 2014. View at Publisher · View at Google Scholar
  9. X.-R. Ren, J. Wei, G. Lei et al., “Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells,” Breast Cancer Research, vol. 14, no. 3, p. R89, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. F. M. Frame and N. J. Maitland, “Cancer stem cells, models of study and implications of therapy resistance mechanisms,” Advances in Experimental Medicine and Biology, vol. 720, pp. 105–118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Rovero, A. Amici, E. Di Carlo et al., “DNA vaccination against rat Her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice,” Journal of Immunology, vol. 165, no. 9, pp. 5133–5142, 2000. View at Google Scholar · View at Scopus
  12. F. Cavallo, R. Offringa, S. H. van der Burg, G. Forni, and C. J. M. Melief, “Vaccination for treatment and prevention of cancer in animal models,” Advances in Immunology, vol. 90, pp. 175–213, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Quaglino, S. Rolla, M. Iezzi et al., “Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions,” Journal of Clinical Investigation, vol. 113, no. 5, pp. 709–717, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Cavallo, A. Astolfi, M. Iezzi et al., “An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention,” BMC Bioinformatics, vol. 6, no. 4, article S7, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. M. Scott, J. P. Allison, and J. D. Wolchok, “Monoclonal antibodies in cancer therapy,” Cancer Immunity, vol. 12, p. 14, 2012. View at Google Scholar · View at Scopus
  16. G. D. Phillips, C. T. Fields, G. Li et al., “Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy,” Clinical Cancer Research, vol. 20, no. 2, pp. 456–468, 2014. View at Publisher · View at Google Scholar
  17. J. Baselga, J. Cortés, S.-B. Kim et al., “Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer,” The New England Journal of Medicine, vol. 366, no. 2, pp. 109–119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Guarneri, E. Barbieri, M. V. Dieci, F. Piacentini, and P. Conte, “Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer,” Cancer Treatment Reviews, vol. 36, supplement 3, pp. S62–S66, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. P. L. Lollini, F. Cavallo, C. De Giovanni, and P. Nanni, “Preclinical vaccines against mammary carcinoma,” Expert Review of Vaccines, vol. 12, no. 12, pp. 1449–1463, 2013. View at Publisher · View at Google Scholar
  20. E. Quaglino, M. Iezzi, C. Mastini et al., “Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice,” Cancer Research, vol. 64, no. 8, pp. 2858–2864, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Porzia, S. Lanzardo, A. Citti et al., “Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies,” Journal of Immunology, vol. 184, no. 8, pp. 4170–4177, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Quaglino, C. Mastini, A. Amici et al., “A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins,” Cancer Research, vol. 70, no. 7, pp. 2604–2612, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Quaglino, F. Riccardo, M. Macagno et al., “Chimeric DNA vaccines against ErbB2+ carcinomas: from mice to humans,” Cancers, vol. 3, no. 3, pp. 3225–3241, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Bolli, E. Quaglino, M. Arigoni et al., “Oncoantigens for an immune prevention of cancer,” The American Journal of Cancer Research, vol. 1, no. 2, pp. 255–264, 2011. View at Google Scholar
  25. L. Vera-Ramirez, P. Sanchez-Rovira, C. L. Ramirez-Tortosa et al., “Gene-expression profiles, tumor microenvironment, and cancer stem cells in breast cancer: latest advances towards an integrated approach,” Cancer Treatment Reviews, vol. 36, no. 6, pp. 477–484, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Goltsov, D. Faratian, S. P. Langdon, P. Mullen, D. J. Harrison, and J. Bown, “Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition,” Cellular Signalling, vol. 24, no. 2, pp. 493–504, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. R. A. Calogero, E. Quaglino, S. Saviozzi, G. Forni, and F. Cavallo, “Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike?” Cancer Immunology, Immunotherapy, vol. 57, no. 11, pp. 1685–1694, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Qian, L. Shen, L. Cheng, Z. Wu, and H. Yao, “B7-H4 expression in various tumors determined using a novel developed monoclonal antibody,” Clinical and Experimental Medicine, vol. 11, no. 3, pp. 163–170, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Lu, K. Singh, S. Mangray et al., “Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype,” Modern Pathology, vol. 26, no. 4, pp. 485–495, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Xing, J.-G. Li, F. Jin et al., “Clinical and biological significance of hepsin overexpression in breast cancer,” Journal of Investigative Medicine, vol. 59, no. 5, pp. 803–810, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Bisig, P. Gaulard, and L. De Leval, “New biomarkers in T-cell lymphomas,” Best Practice and Research: Clinical Haematology, vol. 25, no. 1, pp. 13–28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. W. K. Fang, W. Gu, L. D. Liao et al., “Prognostic significance of desmoglein 2 and desmoglein 3 in esophageal squamous cell carcinoma,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 2, pp. 871–876, 2014. View at Google Scholar
  33. K. K. Haagenson and G. S. Wu, “Mitogen activated protein kinase phosphatases and cancer,” Cancer Biology and Therapy, vol. 9, no. 5, pp. 337–340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Klampfer, “The role of signal transducers and activators of transcription in colon cancer,” Frontiers in Bioscience, vol. 13, no. 8, pp. 2888–2899, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Vader and S. M. A. Lens, “The Aurora kinase family in cell division and cancer,” Biochimica et Biophysica Acta, vol. 1786, no. 1, pp. 60–72, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. E. L. Mayer and I. E. Krop, “Advances in targeting Src in the treatment of breast cancer and other solid malignancies,” Clinical Cancer Research, vol. 16, no. 14, pp. 3526–3532, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. B. N. Rexer and C. L. Arteaga, “Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications,” Cancer Research, vol. 73, no. 13, pp. 3817–3820, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Shafee, C. R. Smith, S. Wei et al., “Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors,” Cancer Research, vol. 68, no. 9, pp. 3243–3250, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Beyer, H. Cao, J. Persson et al., “Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs,” Clinical Cancer Research, vol. 18, no. 12, pp. 3340–3351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Zhou, Y. Zhang, Y. Fu, L. Chan, and A. S. Lee, “Novel mechanism of anti-apoptotic function of 78-kDa glucose-regulated protein (GRP78): endocrine resistance factor in breast cancer, through release of B-cell lymphoma 2 (BCL-2) from BCL-2-interacting killer (BIK),” Journal of Biological Chemistry, vol. 286, no. 29, pp. 25687–25696, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. K. N. Shah, K. R. Mehta, D. Peterson, M. Evangelista, J. C. Livesey, and J. S. Faridi, “AKT-induced tamoxifen resistance is overturned by RRM2 inhibition,” Molecular Cancer Research, vol. 12, no. 3, pp. 394–407, 2014. View at Publisher · View at Google Scholar
  42. L. W. Hebbard, J. Maurer, A. Miller et al., “Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo,” Cancer Research, vol. 70, no. 21, pp. 8863–8873, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. T.-H. Hsieh, C.-F. Tsai, C.-Y. Hsu et al., “Phthalates stimulate the epithelial to mesenchymal transitionthrough an HDAC6-dependent mechanism in human breastepithelial stem cells,” Toxicological Sciences, vol. 128, no. 2, pp. 365–376, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Regan, T. Sourisseau, K. Soady et al., “Aurora A kinase regulates mammary epithelial cell fate by determining mitotic spindle orientation in a Notch-dependent manner,” Cell Reports, vol. 4, no. 1, pp. 110–123, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. V. S. Nair, L. S. Maeda, and J. P. A. Ioannidis, “Clinical outcome prediction by MicroRNAs in human cancer: a systematic review,” Journal of the National Cancer Institute, vol. 104, no. 7, pp. 528–540, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. S. F. Tavazoie, C. Alarcón, T. Oskarsson et al., “Endogenous human microRNAs that suppress breast cancer metastasis,” Nature, vol. 451, no. 7175, pp. 147–152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Urbich, A. Kuehbacher, and S. Dimmeler, “Role of microRNAs in vascular diseases, inflammation, and angiogenesis,” Cardiovascular Research, vol. 79, no. 4, pp. 581–588, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. J. A. Wright, J. K. Richer, and G. J. Goodall, “MicroRNAs and EMT in mammary cells and breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 15, no. 2, pp. 213–223, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Arigoni, G. Barutello, F. Riccardo et al., “MiR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2,” The American Journal of Pathology, vol. 182, no. 6, pp. 2058–2070, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. X. Wang, X. Y. Zhang, B. F. Zhang, C. Q. Yang, X. M. Chen, and H. J. Gao, “Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis,” Journal of Digestive Diseases, vol. 11, no. 1, pp. 50–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. R. R. Lulla, F. F. Costa, J. M. Bischof et al., “Identification of differentially expressed microRNAs in osteosarcoma,” Sarcoma, vol. 2011, Article ID 732690, 6 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. F. F. Costa, J. M. Bischof, E. F. Vanin et al., “Identification of micrornas as potential prognostic markers in ependymoma,” PLoS ONE, vol. 6, no. 10, Article ID e25114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Liu, W. Guo, J. Shi et al., “MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma,” Journal of Hepatology, vol. 56, no. 2, pp. 389–396, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. N. Y. Frank, T. Schatton, and M. H. Frank, “The therapeutic promise of the cancer stem cell concept,” Journal of Clinical Investigation, vol. 120, no. 1, pp. 41–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. L. V. Nguyen, R. Vanner, P. Dirks, and C. J. Eaves, “Cancer stem cells: an evolving concept,” Nature Reviews Cancer, vol. 12, no. 2, pp. 133–143, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Cordero, M. Beccuti, C. Fornari et al., “Multi-level model for the investigation of oncoantigen-driven vaccination effect,” BMC Bioinformatics, vol. 14, supplement 6, p. S11, 2013. View at Google Scholar
  57. E. Fessler, F. E. Dijkgraaf, F. De Sousa E Melo, and J. P. Medema, “Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame?” Cancer Letters, vol. 341, no. 1, pp. 97–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. A. R. Chin and S. E. Wang, “Cytokines driving breast cancer stemness,” Molecular and Cellular Endocrinology, vol. 382, no. 1, pp. 598–602, 2014. View at Publisher · View at Google Scholar
  59. Z. C. Hartman, X.-Y. Yang, O. Glass et al., “HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis,” Cancer Research, vol. 71, no. 13, pp. 4380–4391, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Korkaya, G.-I. Kim, A. Davis et al., “Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population,” Molecular Cell, vol. 47, no. 4, pp. 570–584, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Grange, S. Lanzardo, F. Cavallo, G. Camussi, and B. Bussolati, “SCA-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT trangenic mice,” Neoplasia, vol. 10, no. 12, pp. 1433–1443, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Conti, S. Lanzardo, M. Arigoni et al., “The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells,” The FASEB Journal, vol. 27, no. 12, pp. 4731–4744, 2013. View at Publisher · View at Google Scholar
  63. M. Pickup, S. Novitskiy, and H. L. Moses, “The roles of TGFbeta in the tumour microenvironment,” Nature Reviews Cancer, vol. 13, no. 11, pp. 788–799, 2013. View at Publisher · View at Google Scholar
  64. A. Chiechi, D. L. Waning, K. R. Stayrook, J. T. Buijs, T. A. Guise, and K. S. Mohammad, “Role of TGF- in breast cancer bone metastases,” Advances in Bioscience and Biotechnology, vol. 4, no. 10C, pp. 15–30, 2013. View at Google Scholar
  65. M. E. Bianchi and A. A. Manfredi, “High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity,” Immunological Reviews, vol. 220, no. 1, pp. 35–46, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. P. Scaffidi, T. Misteli, and M. E. Bianchi, “Release of chromatin protein HMGB1 by necrotic cells triggers inflammation,” Nature, vol. 418, no. 6894, pp. 191–195, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Singh, B. M. Simões, S. J. Howell, G. Farnie, and R. B. Clarke, “Recent advances reveal IL-8 signalling as a potential key to targeting breast cancer stem cells,” Breast Cancer Research, vol. 15, no. 4, p. 210, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. J. K. Singh, G. Farnie, N. J. Bundred et al., “Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms,” Clinical Cancer Research, vol. 19, no. 3, pp. 643–656, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Ginestier, S. Liu, M. E. Diebel et al., “CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts,” Journal of Clinical Investigation, vol. 120, no. 2, pp. 485–497, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Tsuyada, A. Chow, J. Wu et al., “CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells,” Cancer Research, vol. 72, no. 11, pp. 2768–2779, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. R. A. Calogero, F. Cordero, G. Forni, and F. Cavallo, “Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice,” Breast Cancer Research, vol. 9, no. 4, article 211, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. I. Conti and B. J. Rollins, “CCL2 (monocyte chemoattractant protein-1) and cancer,” Seminars in Cancer Biology, vol. 14, no. 3, pp. 149–154, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. I. H. Benoy, R. Salgado, P. Van Dam et al., “Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival,” Clinical Cancer Research, vol. 10, no. 21, pp. 7157–7162, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. O. I. Ahmed, A. M. Adel, D. R. Diab, and N. S. Gobran, “Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients,” The Egyptian Journal of Immunology, vol. 13, no. 2, pp. 61–68, 2006. View at Google Scholar · View at Scopus
  75. C.-Y. Li, S. Shan, Q. Huang et al., “Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models,” Journal of the National Cancer Institute, vol. 92, no. 2, pp. 143–147, 2000. View at Google Scholar · View at Scopus
  76. D. J. Hicklin and L. M. Ellis, “Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis,” Journal of Clinical Oncology, vol. 23, no. 5, pp. 1011–1027, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. K. J. Kim, B. Li, J. Winer et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo,” Nature, vol. 362, no. 6423, pp. 841–844, 1993. View at Google Scholar · View at Scopus
  78. A. Grothey and L. M. Ellis, “Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies,” Cancer Journal, vol. 14, no. 3, pp. 170–177, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. D. B. Mendel, A. Douglas Laird, X. Xin et al., “In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship,” Clinical Cancer Research, vol. 9, no. 1 I, pp. 327–337, 2003. View at Google Scholar · View at Scopus
  80. L. Adnane, P. A. Trail, I. Taylor, and S. M. Wilhelm, “Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature,” Methods in Enzymology, vol. 407, pp. 597–612, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. L. J. Wilmes, M. G. Pallavicini, L. M. Fleming et al., “AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging,” Magnetic Resonance Imaging, vol. 25, no. 3, pp. 319–327, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. G. Sonpavde and T. E. Hutson, “Pazopanib: a novel multitargeted tyrosine kinase inhibitor,” Current Oncology Reports, vol. 9, no. 2, pp. 115–119, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. A. J. Ryan and S. R. Wedge, “ZD6474—a novel inhibitor of VEGFR and EGFR tyrosine kinase activity,” British Journal of Cancer, vol. 92, supplement 1, pp. S6–S13, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. U. Vaishampayan, “Cabozantinib as a novel therapy for renal cell carcinoma,” Current Oncology Reports, vol. 15, no. 2, pp. 76–82, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. D. A. Nosov, B. Esteves, O. N. Lipatov et al., “Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma,” Journal of Clinical Oncology, vol. 30, no. 14, pp. 1678–1685, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. D. H. Albert, P. Tapang, T. J. Magoc et al., “Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor,” Molecular Cancer Therapeutics, vol. 5, no. 4, pp. 995–1006, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Giuliano and G. Pagès, “Mechanisms of resistance to anti-angiogenesis therapies,” Biochimie, vol. 95, no. 6, pp. 1110–1119, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Ernkvist, O. Birot, I. Sinha et al., “Differential roles of p80- and p130-angiomotin in the switch between migration and stabilization of endothelial cells,” Biochimica et Biophysica Acta, vol. 1783, no. 3, pp. 429–437, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. B. Troyanovsky, T. Levchenko, G. Månsson, O. Matvijenko, and L. Holmgren, “Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation,” Journal of Cell Biology, vol. 152, no. 6, pp. 1247–1254, 2001. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Bratt, W. J. Wilson, B. Troyanovsky et al., “Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains,” Gene, vol. 298, no. 1, pp. 69–77, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. W. G. Jiang, G. Watkins, A. Douglas-Jones, L. Holmgren, and R. E. Mansel, “Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer,” BMC cancer, vol. 6, article 16, 2006. View at Google Scholar · View at Scopus
  92. E. Y. Lin, J. G. Jones, P. Li et al., “Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases,” The American Journal of Pathology, vol. 163, no. 5, pp. 2113–2126, 2003. View at Google Scholar · View at Scopus
  93. M. Arigoni, G. Barutello, S. Lanzardo et al., “A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors,” Angiogenesis, vol. 15, no. 2, pp. 305–316, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. Y. Zheng, S. Vertuani, S. Nyström et al., “Angiomotin-like protein 1 controls endothelial polarity and junction stability during sprouting angiogenesis,” Circulation Research, vol. 105, no. 3, pp. 260–270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. Q. Li, G. Kondoh, S. Inafuku, Y. Nishimune, and A. Hakura, “Abrogation of c-kit/Steel factor-dependent tumorigenesis by kinase defective mutants of the c-kit receptor: c-kit Kinase defective mutants as candidate tools for cancer gene therapy,” Cancer Research, vol. 56, no. 19, pp. 4343–4346, 1996. View at Google Scholar · View at Scopus
  96. J. L. Regan, H. Kendrick, F.-A. Magnay, V. Vafaizadeh, B. Groner, and M. J. Smalley, “C-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer,” Oncogene, vol. 31, no. 7, pp. 869–883, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. C. Olgasi, P. Dentelli, A. Rosso et al., “DNA vaccination against membrane-bound Kit ligand: a new approach to inhibiting tumour growth and angiogenesis,” European Journal of Cancer, vol. 50, no. 1, pp. 234–246, 2014. View at Publisher · View at Google Scholar
  98. L. Conti, S. Lanzardo, M. Iezzi et al., “Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding αvβ3 integrins,” Contrast Media and Molecular Imaging, vol. 8, no. 4, pp. 350–360, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. P. C. Brooks, R. A. F. Clark, and D. A. Cheresh, “Requirement of vascular integrin αvβ3 for angiogenesis,” Science, vol. 264, no. 5158, pp. 569–571, 1994. View at Google Scholar · View at Scopus
  100. E. Ambrosino, M. Spadaro, M. Iezzi et al., “Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance,” Cancer Research, vol. 66, no. 15, pp. 7734–7740, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. J. M. Park, M. Terabe, D. D. Donaldson, G. Forni, and J. A. Berzofsky, “Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation,” Cancer Immunology, Immunotherapy, vol. 57, no. 6, pp. 907–912, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. S. Bandini, C. Curcio, M. Macagno et al., “Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice,” Oncoimmunology, vol. 2, no. 9, Article ID e26137, 2013. View at Google Scholar
  103. S. E. A. Street, N. Zerafa, M. Iezzi et al., “Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma,” Cancer Research, vol. 67, no. 11, pp. 5454–5460, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. F. Cavallo, C. De Giovanni, P. Nanni, G. Forni, and P.-L. Lollini, “2011: the immune hallmarks of cancer,” Cancer Immunology, Immunotherapy, vol. 60, no. 3, pp. 319–326, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Coscia, E. Quaglino, M. Iezzi et al., “Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway,” Journal of Cellular and Molecular Medicine, vol. 14, no. 12, pp. 2803–2815, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. C. Mastini, P. D. Becker, M. Iezzi et al., “Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice,” Current Cancer Drug Targets, vol. 8, no. 3, pp. 230–242, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. A. Sica, T. Schioppa, A. Mantovani, and P. Allavena, “Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy,” European Journal of Cancer, vol. 42, no. 6, pp. 717–727, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Spadaro, E. Ambrosino, M. Iezzi et al., “Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity,” Clinical Cancer Research, vol. 11, no. 5, pp. 1941–1952, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. L. Cifaldi, E. Quaglino, E. Di Carlo et al., “A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia,” Cancer Research, vol. 61, no. 7, pp. 2809–2812, 2001. View at Google Scholar · View at Scopus
  110. M. Vagliani, M. Rodolfo, F. Cavallo et al., “Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells,” Cancer Research, vol. 56, no. 3, pp. 467–470, 1996. View at Google Scholar · View at Scopus
  111. R. J. Moore, D. M. Owens, G. Stamp et al., “Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis,” Nature Medicine, vol. 5, no. 7, pp. 828–831, 1999. View at Publisher · View at Google Scholar
  112. X. Song, Y. Krelin, T. Dvorkin et al., “CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β-secreting cells,” Journal of Immunology, vol. 175, no. 12, pp. 8200–8208, 2005. View at Google Scholar · View at Scopus
  113. C. Melani, C. Chiodoni, G. Forni, and M. P. Colombo, “Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity,” Blood, vol. 102, no. 6, pp. 2138–2145, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. J. Bromberg, “Stat proteins and oncogenesis,” Journal of Clinical Investigation, vol. 109, no. 9, pp. 1139–1142, 2002. View at Publisher · View at Google Scholar · View at Scopus
  115. B. Almand, J. I. Clark, E. Nikitina et al., “Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer,” Journal of Immunology, vol. 166, no. 1, pp. 678–689, 2001. View at Google Scholar · View at Scopus
  116. C. Melani, S. Sangaletti, F. M. Barazzetta, Z. Werb, and M. P. Colombo, “Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma,” Cancer Research, vol. 67, no. 23, pp. 11438–11446, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. B. Heissig, K. Hattori, S. Dias et al., “Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand,” Cell, vol. 109, no. 5, pp. 625–637, 2002. View at Publisher · View at Google Scholar · View at Scopus
  118. I. Dimova, G. Popivanov, and V. Djonov, “Angiogenesis in cancer—general pathways and their therapeutic implications,” Journal of BUON, vol. 19, no. 1, pp. 15–21, 2014. View at Google Scholar
  119. S. Kusmartsev, E. Eruslanov, H. Kübler et al., “Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma,” Journal of Immunology, vol. 181, no. 1, pp. 346–353, 2008. View at Google Scholar · View at Scopus
  120. B. Hoechst, T. Voigtlaender, L. Ormandy et al., “Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor,” Hepatology, vol. 50, no. 3, pp. 799–807, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. J. Yu, W. Du, F. Yan et al., “Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer,” Journal of Immunology, vol. 190, no. 7, pp. 3783–3797, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. N. Obermajer, J. L. Wong, R. P. Edwards, K. Odunsi, K. Moysich, and P. Kalinski, “PGE2-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells,” Immunological Investigations, vol. 41, no. 6-7, pp. 635–657, 2012. View at Publisher · View at Google Scholar · View at Scopus
  123. Y.-R. Na, Y.-N. Yoon, D.-I. Son, and S.-H. Seok, “Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model,” PLoS ONE, vol. 8, no. 5, Article ID e63451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. B. N. P. Kumar, S. Rajput, K. K. Dey et al., “Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling,” BMC Cancer, vol. 13, article 273, 2013. View at Publisher · View at Google Scholar · View at Scopus
  125. M.-C. Yen, C.-C. Lin, Y.-L. Chen et al., “A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA,” Clinical Cancer Research, vol. 15, no. 2, pp. 641–649, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. C. He, H. Qiao, H. Jiang, and X. Sun, “The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival,” Clinical and Developmental Immunology, vol. 2011, Article ID 695834, 8 pages, 2011. View at Publisher · View at Google Scholar
  127. G. J. Freeman, A. J. Long, Y. Iwai et al., “Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation,” Journal of Experimental Medicine, vol. 192, no. 7, pp. 1027–1034, 2000. View at Publisher · View at Google Scholar · View at Scopus
  128. J.-I. Youn, S. Nagaraj, M. Collazo, and D. I. Gabrilovich, “Subsets of myeloid-derived suppressor cells in tumor-bearing mice,” Journal of Immunology, vol. 181, no. 8, pp. 5791–5802, 2008. View at Google Scholar · View at Scopus
  129. E. Quaglino, C. Mastini, M. Iezzi et al., “The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice,” Vaccine, vol. 23, no. 25, pp. 3280–3287, 2005. View at Publisher · View at Google Scholar · View at Scopus
  130. S. K. Bunt, V. K. Clements, E. M. Hanson, P. Sinha, and S. Ostrand-Rosenberg, “Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4,” Journal of Leukocyte Biology, vol. 85, no. 6, pp. 996–1004, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. X. Tang, “Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer,” Cancer Letters, vol. 332, no. 1, pp. 3–10, 2013. View at Publisher · View at Google Scholar · View at Scopus
  132. S. Rolla, C. Nicoló, S. Malinarich et al., “Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice,” Journal of Immunology, vol. 177, no. 11, pp. 7626–7633, 2006. View at Google Scholar · View at Scopus
  133. H. Von Boehmer, “Mechanisms of suppression by suppressor T cells,” Nature Immunology, vol. 6, no. 4, pp. 338–344, 2005. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Occhipinti, L. Sponton, S. Rolla et al., “Chimeric Rat/Human HER2 efficiently circumvents HER2 tolerance in cancer patients,” Clinical Cancer Research, 2014. View at Publisher · View at Google Scholar
  135. M. G. Strainic, J. Liu, D. Huang et al., “Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells,” Immunity, vol. 28, no. 3, pp. 425–435, 2008. View at Publisher · View at Google Scholar · View at Scopus
  136. M. G. Strainic, E. M. Shevach, F. An, F. Lin, and M. E. Medof, “Absence of signaling into CD4+ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3+ regulatory T cells,” Nature Immunology, vol. 14, no. 2, pp. 162–171, 2013. View at Publisher · View at Google Scholar · View at Scopus
  137. W.-H. Kwan, W. van der Touw, E. Paz-Artal, M. O. Li, and P. S. Heeger, “Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells,” Journal of Experimental Medicine, vol. 210, no. 2, pp. 257–268, 2013. View at Publisher · View at Google Scholar · View at Scopus
  138. P. L. Lollini, G. Nicoletti, L. Landuzzi et al., “Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice,” International Journal of Cancer, vol. 77, no. 6, pp. 937–941, 1998. View at Google Scholar
  139. F. Garrido and I. Algarra, “MHC antigens and tumor escape from immune surveillance,” Advances in Cancer Research, vol. 83, pp. 117–158, 2001. View at Publisher · View at Google Scholar · View at Scopus
  140. M. Inoue, K. Mimura, S. Izawa et al., “Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression,” Oncoimmunology, vol. 1, no. 7, pp. 1104–1110, 2012. View at Publisher · View at Google Scholar
  141. M. Macagno, S. Bandini, L. Stramucci et al., “Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice,” Journal of Immunology, vol. 192, no. 11, pp. 5434–5441, 2014. View at Publisher · View at Google Scholar
  142. R. Tallerico, M. Todaro, S. Di Franco et al., “Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class i molecules,” Journal of Immunology, vol. 190, no. 5, pp. 2381–2390, 2013. View at Publisher · View at Google Scholar · View at Scopus
  143. P. E. Scherer, “Adipose tissue: from lipid storage compartment to endocrine organ,” Diabetes, vol. 55, no. 6, pp. 1537–1545, 2006. View at Publisher · View at Google Scholar · View at Scopus
  144. A. R. Johnson, J. Justin Milner, and L. Makowski, “The inflammation highway: metabolism accelerates inflammatory traffic in obesity,” Immunological Reviews, vol. 249, no. 1, pp. 218–238, 2012. View at Publisher · View at Google Scholar · View at Scopus
  145. R. C. Hovey and L. Aimo, “Diverse and active roles for adipocytes during mammary gland growth and function,” Journal of Mammary Gland Biology and Neoplasia, vol. 15, no. 3, pp. 279–290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  146. Y. Mao, E. T. Keller, D. H. Garfield, K. Shen, and J. Wang, “Stromal cells in tumor microenvironment and breast cancer,” Cancer and Metastasis Reviews, vol. 32, no. 1-2, pp. 303–315, 2013. View at Publisher · View at Google Scholar · View at Scopus
  147. J. Park, D. M. Euhus, and P. E. Scherer, “Paracrine and endocrine effects of adipose tissue on cancer development and progression,” Endocrine Reviews, vol. 32, no. 4, pp. 550–570, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. B. Majed, T. Moreau, K. Senouci, R. J. Salmon, A. Fourquet, and B. Asselain, “Is obesity an independent prognosis factor in woman breast cancer?” Breast Cancer Research and Treatment, vol. 111, no. 2, pp. 329–342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  149. J. Ligibel, “Obesity and breast cancer,” Oncology, vol. 25, no. 11, pp. 994–1000, 2011. View at Google Scholar · View at Scopus
  150. B. Dirat, L. Bochet, M. Dabek et al., “Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion,” Cancer Research, vol. 71, no. 7, pp. 2455–2465, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. K. Sun, C. M. Kusminski, and P. E. Scherer, “Adipose tissue remodeling and obesity,” Journal of Clinical Investigation, vol. 121, no. 6, pp. 2094–2101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  152. B. E. Elliott, S.-P. Tam, D. Dexter, and Z. Q. Chen, “Capacity of adipose tissue to promote growth and metastasis of a murine mammary carcinoma: effect of estrogen and progesterone,” International Journal of Cancer, vol. 51, no. 3, pp. 416–424, 1992. View at Publisher · View at Google Scholar · View at Scopus
  153. J. M. Fleming, T. C. Miller, M. J. Meyer, E. Ginsburg, and B. K. Vonderhaar, “Local regulation of human breast xenograft models,” Journal of Cellular Physiology, vol. 224, no. 3, pp. 795–806, 2010. View at Publisher · View at Google Scholar · View at Scopus
  154. J. Yamaguchi, H. Ohtani, K. Nakamura, I. Shimokawa, and T. Kanematsu, “Prognostic impact of marginal adipose tissue invasion in ductal carcinoma of the breast,” The American Journal of Clinical Pathology, vol. 130, no. 3, pp. 382–388, 2008. View at Publisher · View at Google Scholar · View at Scopus
  155. L. M. Berstein, A. Y. Kovalevskij, T. E. Poroshina et al., “Signs of proinflammatory/genotoxic switch (adipogenotoxicosis) in mammary fat of breast cancer patients: role of menopausal status, estrogens and hyperglycemia,” International Journal of Cancer, vol. 121, no. 3, pp. 514–519, 2007. View at Publisher · View at Google Scholar · View at Scopus
  156. L. Bochet, C. Lehuede, S. Dauvillier et al., “Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer,” Cancer Research, vol. 73, no. 18, pp. 5657–5668, 2013. View at Publisher · View at Google Scholar
  157. M. N. VanSaun, “Molecular pathways: adiponectin and leptin signaling in cancer,” Clinical Cancer Research, vol. 19, no. 8, pp. 1926–1932, 2013. View at Publisher · View at Google Scholar · View at Scopus
  158. N. K. Saxena, L. Taliaferro-Smith, B. B. Knight et al., “Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor,” Cancer Research, vol. 68, no. 23, pp. 9712–9722, 2008. View at Publisher · View at Google Scholar · View at Scopus
  159. A. Eisenberg, E. Biener, M. Charlier et al., “Transactivation of erbB2 by short and long isoforms of leptin receptors,” FEBS Letters, vol. 565, no. 1–3, pp. 139–142, 2004. View at Publisher · View at Google Scholar · View at Scopus
  160. M. L. Gruen, M. Hao, D. W. Piston, and A. H. Hasty, “Leptin requires canonical migratory signaling pathways for induction of monocyte and macrophage chemotaxis,” The American Journal of Physiology—Cell Physiology, vol. 293, no. 5, pp. C1481–C1488, 2007. View at Publisher · View at Google Scholar · View at Scopus
  161. J.-P. Bastard, M. Maachi, C. Lagathu et al., “Recent advances in the relationship between obesity, inflammation, and insulin resistance,” European Cytokine Network, vol. 17, no. 1, pp. 4–12, 2006. View at Google Scholar · View at Scopus
  162. T. Jardé, S. Perrier, M.-P. Vasson, and F. Caldefie-Chézet, “Molecular mechanisms of leptin and adiponectin in breast cancer,” European Journal of Cancer, vol. 47, no. 1, pp. 33–43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  163. A. E. Harvey, L. M. Lashinger, G. Otto, N. P. Nunez, and S. D. Hursting, “Decreased systemic IGF-1 in response to calorie restriction modulates murine tumor cell growth, nuclear factor-κB activation, and inflammation-related gene expression,” Molecular Carcinogenesis, vol. 52, no. 12, pp. 997–1006, 2013. View at Publisher · View at Google Scholar · View at Scopus
  164. D. Chabas, S. E. Baranzini, D. Mitchell et al., “The influence of the proinflammatory cytokine, osteopontin, on autoimmue demyelinating desease,” Science, vol. 294, no. 5547, pp. 1731–1735, 2001. View at Publisher · View at Google Scholar · View at Scopus
  165. M. Mirza, E. Shaughnessy, J. K. Hurley et al., “Osteopontin-c is a selective marker of breast cancer,” International Journal of Cancer, vol. 122, no. 4, pp. 889–897, 2008. View at Publisher · View at Google Scholar · View at Scopus
  166. D. Thorat, A. Sahu, R. Behera et al., “Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers,” Oncology Letters, vol. 6, no. 6, pp. 1559–1564, 2013. View at Google Scholar
  167. S. Meierjohann, M. Schartl, and J.-N. Volff, “Genetic, biochemical and evolutionary facets of Xmrk-induced melanoma formation in the fish Xiphophorus,” Comparative Biochemistry and Physiology C: Toxicology and Pharmacology, vol. 138, no. 3, pp. 281–289, 2004. View at Publisher · View at Google Scholar · View at Scopus
  168. A. C. Cook, A. B. Tuck, S. McCarthy et al., “Osteopontin induces multiple changes in gene expression that reflect the six “hallmarks of cancer” in a model of breast cancer progression,” Molecular Carcinogenesis, vol. 43, no. 4, pp. 225–236, 2005. View at Publisher · View at Google Scholar · View at Scopus
  169. Y.-Y. Wang, C. Lehuédé, V. Laurent et al., “Adipose tissue and breast epithelial cells: a dangerous dynamic duo in breast cancer,” Cancer Letters, vol. 324, no. 2, pp. 142–151, 2012. View at Publisher · View at Google Scholar · View at Scopus
  170. C. H. Stuelten, S. DaCosta Byfield, P. R. Arany, T. S. Karpova, W. G. Stetler-Stevenson, and A. B. Roberts, “Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-α and TGF-β,” Journal of Cell Science, vol. 118, no. 10, pp. 2143–2153, 2005. View at Publisher · View at Google Scholar · View at Scopus
  171. N. Erez, M. Truitt, P. Olson, and D. Hanahan, “Cancer Associated Fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner,” Cancer Cell, vol. 17, no. 2, pp. 135–147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. K. Pietras and A. Östman, “Hallmarks of cancer: interactions with the tumor stroma,” Experimental Cell Research, vol. 316, no. 8, pp. 1324–1331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  173. R. Kalluri and M. Zeisberg, “Fibroblasts in cancer,” Nature Reviews Cancer, vol. 6, no. 5, pp. 392–401, 2006. View at Publisher · View at Google Scholar · View at Scopus
  174. M. Snyder, X.-Y. Huang, and J. J. Zhang, “Signal Transducers and Activators of Transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration,” Journal of Biological Chemistry, vol. 286, no. 45, pp. 38886–38893, 2011. View at Publisher · View at Google Scholar · View at Scopus
  175. I. Barbieri, S. Pensa, T. Pannellini et al., “Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten,” Cancer Research, vol. 70, no. 6, pp. 2558–2567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  176. D. J. Prockop, “Marrow stromal cells as stem cells for nonhematopoietic tissues,” Science, vol. 276, no. 5309, pp. 71–74, 1997. View at Publisher · View at Google Scholar · View at Scopus
  177. S. Maxson, E. A. Lopez, D. Yoo, A. Danilkovitch-Miagkova, and M. A. LeRoux, “Concise review: role of mesenchymal stem cells in wound repair,” Stem Cells Translational Medicine, vol. 1, no. 2, pp. 142–149, 2012. View at Publisher · View at Google Scholar · View at Scopus
  178. E. Spaeth, A. Klopp, J. Dembinski, M. Andreeff, and F. Marini, “Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells,” Gene Therapy, vol. 15, no. 10, pp. 730–738, 2008. View at Publisher · View at Google Scholar · View at Scopus
  179. Y. Rattigan, J.-M. Hsu, P. J. Mishra, J. Glod, and D. Banerjee, “Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu,” Experimental Cell Research, vol. 316, no. 20, pp. 3417–3424, 2010. View at Publisher · View at Google Scholar · View at Scopus
  180. E. Ritter, A. Perry, J. Yu, T. Wang, L. Tang, and E. Bieberich, “Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells,” Annals of Surgery, vol. 247, no. 2, pp. 310–314, 2008. View at Publisher · View at Google Scholar · View at Scopus
  181. R. M. Dwyer, S. M. Potter-Beirne, K. A. Harrington et al., “Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells,” Clinical Cancer Research, vol. 13, no. 17, pp. 5020–5027, 2007. View at Publisher · View at Google Scholar · View at Scopus
  182. Y. Zhang, P. Yang, T. Sun et al., “MiR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis,” Nature Cell Biology, vol. 15, no. 3, pp. 284–294, 2013. View at Publisher · View at Google Scholar · View at Scopus
  183. R. Lotfi, J. Eisenbacher, G. Solgi et al., “Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material,” European Journal of Immunology, vol. 41, no. 7, pp. 2021–2028, 2011. View at Publisher · View at Google Scholar · View at Scopus
  184. A. H. Klopp, E. L. Spaeth, J. L. Dembinski et al., “Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment,” Cancer Research, vol. 67, no. 24, pp. 11687–11695, 2007. View at Publisher · View at Google Scholar · View at Scopus
  185. P. Chaturvedi, D. M. Gilkes, C. C. Wong et al., “Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis,” Journal of Clinical Investigation, vol. 123, no. 1, pp. 189–205, 2013. View at Google Scholar
  186. S. Kidd, E. Spaeth, K. Watson et al., “Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma,” PLoS ONE, vol. 7, no. 2, Article ID e30563, 2012. View at Publisher · View at Google Scholar · View at Scopus
  187. T. Zhang, Y. W. Lee, Y. F. Rui, T. Y. Cheng, X. H. Jiang, and G. Li, “Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors,” Stem Cell Research and Therapy, vol. 4, no. 3, article 70, 2013. View at Publisher · View at Google Scholar · View at Scopus
  188. J. M. Ryan, F. P. Barry, J. M. Murphy, and B. P. Mahon, “Mesenchymal stem cells avoid allogeneic rejection,” Journal of Inflammation, vol. 2, article 8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  189. S. A. Patel, J. R. Meyer, S. J. Greco, K. E. Corcoran, M. Bryan, and P. Rameshwar, “Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-β,” Journal of Immunology, vol. 184, no. 10, pp. 5885–5894, 2010. View at Publisher · View at Google Scholar · View at Scopus
  190. R. S. Waterman, S. L. Tomchuck, S. L. Henkle, and A. M. Betancourt, “A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype,” PLoS ONE, vol. 5, no. 4, Article ID e10088, 2010. View at Publisher · View at Google Scholar · View at Scopus
  191. J. Lei, Z. Wang, D. Hui et al., “Ligation of TLR2 and TLR4 on murine bonTritschler I.e marrow-derived mesenchymal stem cells triggers differential effects on their immunosuppressive activity,” Cellular Immunology, vol. 271, no. 1, pp. 147–156, 2011. View at Publisher · View at Google Scholar · View at Scopus
  192. M. Pevsner-Fischer, V. Morad, M. Cohen-Sfady et al., “Toll-like receptors and their ligands control mesenchymal stem cell functions,” Blood, vol. 109, no. 4, pp. 1422–1432, 2007. View at Publisher · View at Google Scholar · View at Scopus
  193. S. Liu, C. Ginestier, S. J. Ou et al., “Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks,” Cancer Research, vol. 71, no. 2, pp. 614–624, 2011. View at Publisher · View at Google Scholar · View at Scopus
  194. H.-J. Li, F. Reinhardt, H. R. Herschman, and R. A. Weinberg, “Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 Signaling,” Cancer Discovery, vol. 2, no. 9, pp. 840–855, 2012. View at Publisher · View at Google Scholar · View at Scopus
  195. X.-L. Yan, C.-J. Fu, L. Chen et al., “Mesenchymal stem cells from primary breast cancer tissue promote cancer proliferation and enhance mammosphere formation partially via EGF/EGFR/Akt pathway,” Breast Cancer Research and Treatment, vol. 132, no. 1, pp. 153–164, 2012. View at Publisher · View at Google Scholar · View at Scopus
  196. E. Devarajan, Y.-H. Song, S. Krishnappa, and E. Alt, “Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells,” International Journal of Cancer, vol. 131, no. 5, pp. 1023–1031, 2012. View at Publisher · View at Google Scholar · View at Scopus
  197. Q. Xu, L. Wang, H. Li et al., “Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial-mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-β,” International Journal of Oncology, vol. 41, no. 3, pp. 959–968, 2012. View at Publisher · View at Google Scholar · View at Scopus
  198. A. De Luca, L. Lamura, M. Gallo, V. Maffia, and N. Normanno, “Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration,” Journal of Cellular Biochemistry, vol. 113, no. 11, pp. 3363–3370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  199. A. E. Karnoub, A. B. Dash, A. P. Vo et al., “Mesenchymal stem cells within tumour stroma promote breast cancer metastasis,” Nature, vol. 449, no. 7162, pp. 557–563, 2007. View at Publisher · View at Google Scholar · View at Scopus
  200. J. L. Halpern, A. Kilbarger, and C. C. Lynch, “Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor,” Cancer Letters, vol. 308, no. 1, pp. 91–99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  201. S. Y. Shin, J.-S. Nam, Y. Lim, and Y. H. Lee, “TNFα-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines,” Journal of Biological Chemistry, vol. 285, no. 40, pp. 30731–30740, 2010. View at Publisher · View at Google Scholar · View at Scopus
  202. L. V. Rhodes, J. W. Antoon, S. E. Muir, S. Elliott, B. S. Beckman, and M. E. Burow, “Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk,” Molecular Cancer, vol. 9, article 295, 2010. View at Publisher · View at Google Scholar · View at Scopus
  203. M. Studeny, F. C. Marini, J. L. Dembinski et al., “Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents,” Journal of the National Cancer Institute, vol. 96, no. 21, pp. 1593–1603, 2004. View at Publisher · View at Google Scholar · View at Scopus
  204. X.-C. Chen, R. Wang, X. Zhao et al., “Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs,” Carcinogenesis, vol. 27, no. 12, pp. 2434–2441, 2006. View at Publisher · View at Google Scholar · View at Scopus
  205. M. R. Loebinger, A. Eddaoudi, D. Davies, and S. M. Janes, “Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer,” Cancer Research, vol. 69, no. 10, pp. 4134–4142, 2009. View at Publisher · View at Google Scholar · View at Scopus
  206. L. Kucerova, V. Altanerova, M. Matuskova, S. Tyciakova, and C. Altaner, “Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy,” Cancer Research, vol. 67, no. 13, pp. 6304–6313, 2007. View at Publisher · View at Google Scholar · View at Scopus
  207. N. Serakinci, U. Fahrioglu, and R. Christensen, “Mesenchymal stem cells, cancer challenges and new directions,” European Journal of Cancer, vol. 50, no. 8, pp. 1522–1530, 2014. View at Publisher · View at Google Scholar